Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CDTX 
Cidara Therapeutics Inc (CDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CDTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $61.8
1 Year Target Price $61.8
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.63% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.02B USD | Price to earnings Ratio - | 1Y Target Price 61.8 |
Price to earnings Ratio - | 1Y Target Price 61.8 | ||
Volume (30-day avg) 5 | Beta 0.8 | 52 Weeks Range 10.14 - 56.83 | Updated Date 07/1/2025 |
52 Weeks Range 10.14 - 56.83 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -26.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -35743.71% |
Management Effectiveness
Return on Assets (TTM) -55.2% | Return on Equity (TTM) -299.58% |
Valuation
Trailing PE - | Forward PE 5.75 | Enterprise Value 851865820 | Price to Sales(TTM) 3374.93 |
Enterprise Value 851865820 | Price to Sales(TTM) 3374.93 | ||
Enterprise Value to Revenue 2820.75 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 20924400 | Shares Floating 12019265 |
Shares Outstanding 20924400 | Shares Floating 12019265 | ||
Percent Insiders 1.12 | Percent Institutions 55.45 |
Analyst Ratings
Rating 2 | Target Price 61.8 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cidara Therapeutics Inc
Company Overview
History and Background
Cidara Therapeutics Inc. was founded in 2012. It is a biotechnology company focused on developing novel anti-infectives to treat fungal and bacterial infections. They have focused on the discovery, development, and commercialization of therapies designed to improve the lives of patients suffering from serious infections.
Core Business Areas
- Antifungal Program: Focused on developing and commercializing rezafungin, a novel echinocandin antifungal for the treatment and prevention of serious fungal infections.
- Immunotherapeutic Program: Previously, the company pursued other therapeutic candidates. However, due to financial struggles, most of the portfolio was let go.
Leadership and Structure
Jeffrey Stein is the current President and CEO. The company is structured around research and development, clinical operations, and commercial strategy.
Top Products and Market Share
Key Offerings
- Rezafungin: Rezafungin is Cidara's lead product candidate, an echinocandin antifungal being developed for the treatment and prevention of serious fungal infections. While market share data is unavailable prior to launch, its target market includes hospital-treated fungal infections, where competitors include caspofungin (Merck), micafungin (Astellas), and anidulafungin (Pfizer).
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of drug-resistant infections and the need for novel therapies. The antifungal segment is characterized by established players and a growing demand for broad-spectrum treatments.
Positioning
Cidara aims to address unmet needs in the treatment of serious fungal infections with rezafungin, potentially offering advantages over existing echinocandins in terms of dosing and spectrum of activity.
Total Addressable Market (TAM)
The global antifungal drugs market is projected to reach billions of dollars. Cidara's positioning is dependent on the success of rezafungin and its eventual market share in this large TAM.
Upturn SWOT Analysis
Strengths
- Novel echinocandin antifungal (rezafungin)
- Targeting unmet needs in serious fungal infections
- Potential for improved dosing regimen over existing treatments
Weaknesses
- Reliance on a single lead product candidate
- Limited financial resources and dependence on partnerships
- High competition in the anti-infectives market
Opportunities
- Potential FDA approval and commercialization of rezafungin
- Strategic partnerships for development and commercialization
- Expansion into new indications or geographies
Threats
- Clinical trial failures or delays
- Regulatory hurdles and market access challenges
- Competition from established players and new entrants
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ASTL.L
Competitive Landscape
Cidara faces stiff competition from established pharmaceutical companies with broad portfolios and extensive resources. Its success depends on demonstrating the clinical and economic advantages of rezafungin.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been challenging due to the company's focus on a single product and its dependence on external funding.
Future Projections: Future growth is heavily dependent on the success of rezafungin and potential partnerships.
Recent Initiatives: Recent initiatives include advancing the clinical development of rezafungin and seeking strategic partnerships.
Summary
Cidara Therapeutics is a biotechnology company focused on anti-infectives, primarily rezafungin. The company faces significant risks, including reliance on a single product, strong competition, and dependence on partnerships. Success hinges on rezafungin's regulatory approval and commercialization. Its strengths lie in its novel antifungal candidate, but weaknesses lie in its financials. Investors should carefully consider its risks and potential before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial professional. Financials provided above are hyphothetical.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cidara Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-15 | President, CEO & Executive Director Dr. Jeffrey L. Stein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.cidara.com |
Full time employees 38 | Website https://www.cidara.com | ||
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.